10-Q: Alnylam Soars on Strong Product Sales, Zilebesiran Milestone

Alnylam Pharmaceuticals reported a significant increase in total revenues and net income for the third quarter and first nine months of 2025, driven by robust AMVUTTRA sales and a major milestone payment from Roche for zilebesiran.

Summary

• Total revenues for the three months ended September 30, 2025, increased by 149% to $1.25 billion, compared to $500.9 million for the same period in 2024.
• Net income for the three months ended September 30, 2025, was $251.1 million, a significant improvement from a net loss of $111.6 million in the prior year period.
• Net product revenues for the quarter grew 103% to $851.1 million, primarily driven by AMVUTTRA sales, especially in the U.S. for ATTR amyloidosis with cardiomyopathy.
• Net revenues from collaborations increased significantly by over 500% to $351.7 million for the quarter, largely due to a $300.0 million milestone payment from Roche for zilebesiran.
• Royalty revenue doubled to $46.2 million for the quarter, mainly from increased global net sales of Leqvio by Novartis.
• The company initiated the ZENITH Phase 3 cardiovascular outcomes trial for zilebesiran and the TRITON-CM Phase 3 clinical trial for nucresiran.
• Regeneron announced positive Phase 3 results for cemdisiran in generalized myasthenia gravis, with a U.S. regulatory submission planned for Q1 2026.
• Alnylam issued $661.3 million in 0.00% Convertible Senior Notes due 2028 and used a portion of the proceeds to repurchase $637.8 million of its 1.00% Convertible Senior Notes due 2027 for approximately $1.11 billion.
• A new $500.0 million revolving credit agreement was established, maturing in September 2030, with no borrowings outstanding as of September 30, 2025.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue growth and a return to net profitability, driven by successful product commercialization and key pipeline milestones. While there are inherent industry risks and increased operating expenses, the overall trajectory and strategic execution are highly positive.

Positives

• Total revenues increased by 149% to $1.25 billion for the three months ended September 30, 2025, and by 58% to $2.62 billion for the nine months ended September 30, 2025.
• Net income reached $251.1 million for the three months ended September 30, 2025, and $127.3 million for the nine months ended September 30, 2025, a significant turnaround from losses in the prior year periods.
• AMVUTTRA net product revenues surged by 165% to $685.3 million for the quarter, driven by increased patient demand, particularly for ATTR amyloidosis with cardiomyopathy in the U.S.
• A $300.0 million development milestone payment was received from Roche in September 2025 upon the first patient dosing in the ZENITH Phase 3 study for zilebesiran.
• Qfitlia (fitusiran), a product commercialized by Sanofi, received FDA approval in March 2025 for hemophilia A or B.
• Regeneron announced positive topline results from the Phase 3 NIMBLE clinical trial of cemdisiran in generalized myasthenia gravis, meeting primary and key secondary endpoints.
• Nucresiran (formerly ALN-TTRsc04) showed positive Phase 1 results with mean reductions of serum TTR greater than 90% sustained through at least Day 180, and Phase 3 trials (TRITON-CM and TRITON-PN) are underway.
• Mivelsiran (formerly ALN-APP) Phase 1 data demonstrated robust, durable, dose-dependent reductions of soluble amyloid precursor protein beta (sAPP) in cerebrospinal fluid for Alzheimer's disease.
• The company's cash, cash equivalents, and marketable securities totaled $2.72 billion as of September 30, 2025, an increase from $2.69 billion at December 31, 2024.

Negatives

• ONPATTRO net product revenues decreased by 22% to $39.1 million for the quarter, primarily due to patient switches to AMVUTTRA.
• Total operating costs and expenses increased by 52% to $881.0 million for the three months ended September 30, 2025, and by 30% to $2.25 billion for the nine months ended September 30, 2025.
• A loss related to convertible debt of $39.1 million was recorded for the three and nine months ended September 30, 2025, due to an inducement expense from the partial repurchase of 2027 Notes.
• Other expense, net, increased by 306% to $129.0 million for the quarter, driven by increased loss from the change in fair value of development derivative liability and higher interest expense.
• The accumulated deficit, while reduced, remains substantial at $7.16 billion as of September 30, 2025.

Risks

• The marketing and sale of approved products, including AMVUTTRA for ATTR amyloidosis with cardiomyopathy, or any future products, may be unsuccessful or less successful than anticipated.
• The company has a history of losses and may not become and remain profitable, despite targeting financial self-sustainability by the end of 2025.
• Substantial funds will be required to continue research, development, and commercialization activities, and greater funds than estimated may be needed, potentially limiting or ceasing certain activities.
• Inability to maintain existing or enter into new collaborations, or failure of collaborators to perform obligations, could delay or terminate product development and commercialization.
• Significant costs are expected for growing manufacturing capabilities, and reliance on third parties for manufacturing products and product candidates poses risks of supply disruption.
• Reliance on third parties to conduct clinical trials means their failure to fulfill obligations could adversely affect development plans.
• Difficulty in attracting and retaining qualified key management and scientific, development, medical, and commercial staff could adversely affect business plan implementation.
• Expanding operations globally from a U.S.and EU-based company to a multi-product global company may be challenging.
• Any product candidate may fail in development or experience significant delays, and earlier clinical trial results may not be indicative of future outcomes.
• Undesirable side effects or unexpected adverse properties of products or product candidates could delay or prevent regulatory approval, limit commercial potential, or result in negative consequences post-approval (e.g., mivelsiran partial clinical hold).
• Inability to obtain U.S. or foreign regulatory approval for product candidates could prevent commercialization.
• Approved products are subject to extensive and ongoing regulatory oversight; failure to comply could lead to limited or withdrawn approvals and other penalties.
• Significant liability may be incurred if enforcement authorities allege or determine engagement in commercial activities for unapproved product candidates or off-label promotion of approved products.
• Even with regulatory approval, the market may not be receptive to product candidates upon commercial introduction, affecting business and financial condition.
• Products may become subject to unfavorable pricing regulations or healthcare reform initiatives, harming business and financial condition.
• Inability to achieve and maintain coverage and adequate reimbursement from third-party payors for products could severely hinder commercial success.
• Non-compliance with U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws could impair global competitiveness.
• Governments outside the U.S. may impose strict price controls, adversely affecting revenues.
• Failure to comply with broad and complex healthcare and other laws could lead to substantial penalties (e.g., U.S. Attorney's Office subpoena regarding government price reporting).
• Substantial risk of product liability claims exists, and insufficient insurance could adversely affect the business.
• Employee misconduct or improper activities, including noncompliance with regulatory standards or insider trading, could significantly harm the business.
• Failure to comply with environmental, health, and human safety laws could adversely affect the business.
• Inability to obtain and enforce patent protection for discoveries, or challenges to existing patent rights, could harm the ability to develop and commercialize products.
• Dependence on licensed patent rights from third-party owners means their failure to properly obtain, maintain, or enforce patents could harm the competitive position.
• Intellectual property litigation or other proceedings could incur substantial costs and expenses, and potentially lead to liability or cessation of development/commercialization efforts.
• Failure to comply with obligations under licenses or related agreements could result in damages or loss of necessary rights.
• The pharmaceutical market is intensely competitive, and inability to compete effectively could hinder successful commercialization.
• Competition from companies developing novel drugs and technology platforms similar to or more effective than Alnylam's could adversely affect commercialization.
• Stock price volatility and potential decline due to various market and company-specific factors.
• Insufficient cash flow to pay indebtedness, including convertible notes, or to repurchase notes upon a fundamental change.
• The conditional conversion feature of the convertible notes, if triggered, may adversely affect liquidity.
• Transactions relating to convertible notes may affect the value of common stock, including potential dilution.
• Subject to counterparty risk with respect to capped call transactions.
• Holders of 2028 Notes may not earn a return on investment as they do not bear regular interest.
• The accounting method for convertible debt securities could materially affect reported financial results, potentially reducing diluted EPS or reclassifying debt as current liability.

Future Outlook

Alnylam is focused on its 'Alnylam P 5 x25' strategy, aiming to become a top-tier biotech company by the end of 2025 and achieve sustainable operating profitability beginning in 2025. The company expects continued investment in research and development, including advancing multiple late-stage clinical programs like zilebesiran and nucresiran, and expanding its global commercial infrastructure. Liquidity from current cash, cash equivalents, marketable securities, and the new revolving credit agreement is believed to be sufficient to cover capital and operating needs for at least the next 12 months.

Management Comments

• Yvonne L. Greenstreet, M.D., Chief Executive Officer, entered into a Rule 10b5-1 trading plan on August 13, 2025, to sell up to 25,650 shares of common stock received as equity incentive compensation, with sales occurring between November 11, 2025, and May 14, 2026, if market prices are above specified levels.
• Kevin J. Fitzgerald, Ph.D., Chief Scientific Officer, entered into a Rule 10b5-1 trading plan on August 14, 2025, to sell up to 30,013 shares of common stock received as equity incentive compensation, with sales occurring between November 12, 2025, and August 15, 2026.

Industry Context

Alnylam operates in the intensely competitive and rapidly changing pharmaceutical and biotechnology market, particularly in the RNAi therapeutics space. The company's strong product revenue growth, especially from AMVUTTRA, and significant pipeline advancements like zilebesiran and cemdisiran, position it as a leader in rare and prevalent disease areas. However, it faces ongoing competition from established pharmaceutical companies and emerging biotech firms developing alternative therapies, including oral medications for ATTR amyloidosis and other RNAi-based drugs. The industry is also navigating evolving regulatory landscapes, including increased scrutiny on drug pricing and marketing practices, as well as complex data privacy regulations, which could impact commercialization efforts and operational costs.

Comparison to Industry Standards

• AMVUTTRA for ATTR amyloidosis with cardiomyopathy competes with Pfizer's VYNDAQEL/VYNDAMAX (tafamidis) and BridgeBio's ATTRUBY (acoramidis), both of which are oral medications and available at lower list prices, potentially impacting AMVUTTRA's commercial success despite its competitive profile.
• For hATTR amyloidosis with polyneuropathy, AMVUTTRA and ONPATTRO compete with Ionis's TEGSEDI (inotersen) and AstraZeneca/Ionis's WAINUA (eplontersen), both subcutaneously administered, and Pfizer's VYNDAQEL/VYNDAMAX (tafamidis) in pill form.
• OXLUMO for PH1 faces competition from Novo Nordisk's RIVFLOZA (nedosiran), a once-monthly subcutaneous RNAi therapy approved in September 2023 and launched in early 2024, as well as investigational drugs from Biocodex, M8 Pharmaceuticals, and YolTech Therapeutics.
• In the broader RNAi therapeutic field, Alnylam competes with companies like Arrowhead, Takeda, Janssen, GlaxoSmithKline, Amgen, Quark Pharmaceuticals, Roche, Silence Therapeutics, Arbutus, Sylentis, Novo Nordisk, Aro Biotherapeutics, Boehringer Ingelheim, Eli Lilly and Company, and its collaborators Regeneron, Sanofi, and Vir.
• The company also faces competition from antisense-based drugs, such as those developed by Ionis (e.g., WAINUA, TEGSEDI), which target mRNAs to suppress gene activity.

Legal Proceedings

• Settled separate patent infringement lawsuits against Moderna, Inc. and Pfizer Inc. in August and September 2025, respectively, related to their mRNA COVID-19 vaccines.
• Acuitas Therapeutics, Inc.'s declaratory judgment action seeking to add co-inventors on patents asserted against Pfizer/BioNTech and Moderna was dismissed without prejudice by the District Court on July 1, 2025.
• A lawsuit filed by The Board of Regents of the University of Texas System in December 2024, alleging infringement of a patent by making, using, and commercializing ONPATTRO in the U.S., remains pending, with a renewed motion to dismiss and transfer filed by Alnylam on September 24, 2025.
• Received a subpoena from the U.S. Attorney's Office for the District of Massachusetts in October 2025, seeking documents pertaining to government price reporting for AMVUTTRA, ONPATTRO, OXLUMO, and GIVLAARI, including fee and discount arrangements with distributors.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong financial performance and pipeline progress, but also risks of stock price volatility and dilution from convertible notes.
• Patients: Benefit from new drug approvals (e.g., AMVUTTRA for cardiomyopathy, Qfitlia for hemophilia) and advancements in investigational therapies (zilebesiran, nucresiran, cemdisiran, mivelsiran), but also face risks of side effects and access limitations.
• Employees: Growth in workforce and global operations, but also exposure to risks of misconduct and compliance requirements.
• Collaborators (Roche, Regeneron, Novartis, Sanofi, Vir): Continued collaboration revenues and shared development efforts, but also potential for disputes or changes in strategic focus.
• Government/Regulatory Bodies: Subject to ongoing regulatory oversight, pricing scrutiny, and investigations (e.g., U.S. Attorney's Office subpoena), requiring significant compliance efforts and potential penalties.
• Creditors (Convertible Note Holders, Lenders): Impacted by the company's ability to service debt and potential for conversion or repurchase of notes.

Next Steps

• Continue global regulatory filings and product launches for AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
• Advance zilebesiran through the ZENITH Phase 3 cardiovascular outcomes trial.
• Initiate the TRITON-PN Phase 3 clinical trial of nucresiran in patients with hATTR polyneuropathy.
• Initiate a Phase 2 clinical trial of mivelsiran in patients with Alzheimer's disease in the fourth quarter of 2025.
• Regeneron plans a U.S. regulatory submission for cemdisiran monotherapy in the first quarter of 2026, pending discussions with the FDA.
• Continue to build and leverage global commercial infrastructure and enhance the global compliance program.
• Consider alternatives to repurchase or redeem the remaining $397.2 million aggregate principal amount of 2027 Notes outstanding.

Key Dates

Recommendation

Alnylam's Q3 2025 results demonstrate exceptional financial performance, marked by a significant return to net profitability and robust revenue growth, primarily driven by the strong commercialization of AMVUTTRA and a substantial milestone payment from Roche for zilebesiran. The company's pipeline is advancing with multiple Phase 3 trials initiated for nucresiran and zilebesiran, and positive Phase 3 results for cemdisiran. These developments underscore strong execution on the 'Alnylam P 5 x25' strategy to achieve sustainable operating profitability. While the company operates in a competitive and regulated environment with inherent risks, the current momentum in both commercial and clinical fronts, coupled with a solid liquidity position, presents a compelling 'strong buy' opportunity for seasoned investors looking for growth in the RNAi therapeutics space.

Keywords

Alnylam, RNAi therapeutics, AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, Zilebesiran, Nucresiran, Cemdisiran, Qfitlia, Leqvio, ATTR amyloidosis, Hypertension, Hemophilia, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1, Alzheimer's Disease, Clinical trials, Biotechnology, Pharmaceuticals, SEC filing, 10-Q, Financial results, Drug development, Commercialization, Collaborations